SAGE Therapeutics (SAGE) Tops Q3 EPS by 1c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.53), $0.01 better than the analyst estimate of ($1.54). Revenue for the quarter came in at $11.87 million versus the consensus estimate of $10.8 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Creatd files Form S-1 and reports Q1 2026 financial results
• Bernstein SocGen Highlights an 'Enhanced Buying Opportunity' at CRH plc (CRH)